Ginkgo Bioworks went public via a SPAC merger with Soaring Eagle in a $15bn deal.

Ginkgo Bioworks, a biotech company, went public via a SPAC merger with Soaring Eagle Acquisition in a $15bn deal. Investors have provided $775m in PIPE, with investments from Baillie Gifford, Putnam Investments, Counterpoint Global, ARK Invest, ArrowMark Partners, Bain Capital, Berkshire Partners, Franklin, Cascade Investment, Casdin Capital, General Atlantic, Senator Investment Group, T. Rowe Price Associates, Viking Global, Eagle Equity and Bellco Capital. "For nearly two decades, my co-founders and I have been on a mission to make programming cells as easy as programming computers. Today marks an important milestone not only for the team at Ginkgo, but for synthetic biology as a whole, and I am thrilled to work with our team, partners and investors as we continue scaling our platform to solve even bigger problems with biology," Jason Kelly, Ginkgo Bioworks Co-Founder and CEO.